OIG Audit Finds Medicare Paid for Drugs That Didn't Qualify for Coverage

Medicare spent hundreds of millions of dollars covering over-the-counter (OTC) drugs that did not meet the program's eligibility rules, according to an audit by the U.S. Department of Health and Human Services Office of Inspector General (HHS OIG), reported September 2, 2026 by Healthcare Dive. The HHS OIG is the federal watchdog that reviews Medicare and Medicaid spending for waste, fraud, and improper payments. The audit places responsibility on the Centers for Medicare & Medicaid Services (CMS), the federal agency that administers Medicare, saying its oversight of these claims was inadequate. CMS has concurred with the audit's findings, according to the source report.

The full audit details on which drugs, which plan types, and what specific oversight breakdowns occurred were not included in the available reporting. What is clear is the scale: the improper spending reached into the hundreds of millions of dollars, a figure large enough that OIG flagged it as a systemic oversight failure rather than a handful of isolated billing errors.

Key Takeaway

An HHS OIG audit found Medicare paid hundreds of millions of dollars for over-the-counter drugs that shouldn't have been covered, and blamed weak CMS oversight. CMS has agreed with the findings. This is a program-integrity finding about federal claims processing, not evidence that any individual beneficiary or pharmacy did anything wrong.

Why an Oversight Gap at CMS Matters for Coverage Rules

When CMS's claims-review systems don't catch ineligible items before payment, the gap doesn't just cost the Medicare trust fund money, it also signals that the automated and manual checks meant to keep coverage consistent with program rules aren't working as designed. Medicare's OTC drug coverage typically flows through specific channels, such as Medicare Advantage plan supplemental benefits or Part D formularies, each with its own rules about which products qualify. An audit like this one is a reminder that those rules exist for a reason: not every OTC product a pharmacy or plan submits for reimbursement is automatically eligible, even if a claim gets approved and paid.

CMS's agreement with the audit findings, as reported, suggests the agency is not disputing the core conclusion and may move to tighten claims-edit rules or provider guidance in response. Readers should watch for follow-up CMS guidance or plan-level notices in the months ahead, since agencies that concur with an OIG audit typically commit to a corrective action plan, even when the audit report itself doesn't spell out the timeline.

What This Means for Medicare Advantage and Part D Enrollees

For most individual enrollees, this audit is unlikely to translate into a bill or a clawback demand, since the improper payments described were made by Medicare to providers or plans, not to beneficiaries directly. But it's still relevant to anyone using an OTC benefit card, mail-order pharmacy allowance, or Part D drug coverage, because it highlights that coverage determinations aren't foolproof. A drug or product appearing on a plan's OTC catalog or being processed at checkout doesn't guarantee it was, in fact, an eligible expense under Medicare's rules, at least not with the level of certainty the program is supposed to provide.

What Medicare Enrollees Should Check Now

This audit doesn't require immediate action from most beneficiaries, but it's a good prompt to review a few things:

Check your Explanation of Benefits (EOB) or Medicare Summary Notice. These documents list what was billed to Medicare on your behalf. If something looks unfamiliar, such as a drug or product you didn't purchase or use, contact your plan or 1-800-MEDICARE to ask about it.

Understand what your OTC allowance actually covers. Medicare Advantage plans that offer OTC benefit cards publish an approved product catalog. Reviewing it before you shop can prevent a claim from being flagged or denied later, and helps you understand which purchases are backed by real Medicare coverage rules versus plan marketing.

Watch for CMS or plan communications about coverage changes. If CMS tightens its claims-edit process in response to this audit, some plans may update their OTC catalogs or documentation requirements. That could mean new paperwork or verification steps at the pharmacy counter.

Compare plans with oversight and transparency in mind. If you're shopping for a Medicare Advantage or Part D plan during Fall Open Enrollment (October 15 through December 7, 2026) or another enrollment window, ask a licensed agent how a plan's OTC benefit works, what's covered, and how claims are verified. Senior Plan Path can help you compare Medicare plans and connect with a licensed agent who can walk through these details for your specific situation.

Read the original Healthcare Dive report for more on the audit at healthcaredive.com.